Antiphospholipid-Syndrom: neue Klassifikationskriterien und Implikationen für die Praxis

Zusammenfassung

Analog zu anderen entzündlich-rheumatischen Erkrankungen wurden im Oktober 2023 neue hierarchisch gruppierte, gewichtete und risikostratifizierte APS Klassifikationskriterien von der European League Against Rheumatism (EULAR) gemeinsam mit dem American College of Rheumatology (ACR) vorgestellt. Die neuen Kriterien sehen als obligates Eingangskriterium das Vorliegen mindestens einer klinischen APS-Manifestation und eines positiven aPL-Labortests vor (Lupusantikoagulans oder moderat bis deutlich erhöhte IgG- oder IgM-Titer für aCL oder aß2GPI). Die sechs Klinik- und zwei Labordomänen werden mit Werten von 1–7 Punkten gewichtet. Eine Klassifikation als APS kann erfolgen, wenn mindestens jeweils 3 Punkte in den klinischen und den serologischen Domänen erreicht werden. Neu werden traditionelle Thromboserisikofaktoren bei aPL-positiven Personen mitberücksichtigt und eine genauere Charakterisierung aPL-assoziierter mikrovaskulärer, geburtshilflicher und nichtthrombotischer Manifestationen (Thrombozytopenie und Herzklappenbeteiligung) vorgenommen. IgM-aPL zählen als weniger spezifisch und werden mit einer deutlich geringeren Punktezahl (1 Punkt) gegenüber den IgG-aPL (je nach Höhe und Konstellation 4-7 Punkte) berücksichtigt. Die erreichte hohe Spezifität der neuen Klassifikationskriterien wird qualitativ hochwertige Studien im APS mit dem Ziel einer verbesserten Patientenversorgung erlauben. Der Beitrag fokussiert auf aktuelle Herausforderungen durch die Klassifikationskriterien sowie die unabhängig zu sehenden Aspekte der klinischen Diagnosestellung und der daraus erwachsenen Behandlungskonsequenzen.

Abstract

As has been done with other inflammatory rheumatic diseases, new hierarchically grouped, weighted and risk-stratified classification criteria were introduced for Antiphospholipid Syndrome (APS) by the European League Against Rheumatism (EULAR) in collaboration with the American College of Rheumatology (ACR) in October 2023. The new criteria stipulate the mandatory presence of at least one clinical manifestation of APS and a positive aPL laboratory test (lupus anticoagulant or moderately to significantly elevated IgG or IgM titres for aCL or anti-β2GPI) as the entry criteria. The six clinical and two laboratory domains are weighted with values ranging from 1 to 7 points. A classification as APS requires a minimum of 3 points in both the clinical and serological domains. Traditional thrombosis risk factors are now taken into consideration in aPL-positive individuals, and a more detailed characterization of aPL-associated microvascular, obstetric and non-thrombotic clinical manifestations (thrombocytopenia and heart valve involvement) is taken into account. IgM-aPL is considered less specific and is assigned a significantly lower point value (1 point) compared with IgG-aPL (4-7 points depending on the level and constellation). The high specificity associated with the new classification criteria will allow for high-quality studies in APS with the aim of improving patient care. This paper focuses on current challenges posed by the classification criteria as well as aspects to be considered for clinical diagnosis, including treatment consequences.

Schlüsselwörter

APS - Klassifikationskriterien 2023 - Diagnose

Keywords

APS - classification criteria 2023 - diagnosis

Publication History

Article published online:
17 April 2024

• Literatur

• 1 Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med 2018; 378: 2010-2021
• 2 Neville C, Rauch J, Kassis J. et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thrombosis and haemostasis 2003; 90: 108-115
• 3 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases 2019; 78: 1296-1304
• 4 Cervera R. Antiphospholipid syndrome. Thrombosis Research 2017; 151: S43-S47
• 5 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006; 4: 295-306
• 6 Barbhaiya M, Zuily S, Naden R. et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol 2023; 75: 1687-1702
• 7 Aringer M, Costenbader K, Daikh D. et al. European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019; 71: 1400-1412
• 8 Abreu MM, Danowski A, Wahl DG. et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14^th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features. Autoimmunity reviews 2015; 14: 401-414
• 9 Sciascia S, Amigo MC, Roccatello D. et al. Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. Nat Rev Rheumatol 2017; 13: 548-60
• 10 Nguyen Y, Yelnik CM, Morel N. et al. Determination of four homogeneous subgroups of patients with antiphospholipid syndrome: a cluster analysis based on 509 cases. Rheumatology. 2022; 62: 2813-2819
• 11 Guedon AF, Ricard L, Laurent C. et al. Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study. RMD Open 2023; 9: e002881 DOI: 10.1136/rmdopen-2022-002881.
• 12 Barbhaiya M, Erkan D, Ahmadzadeh Y. et al. Op0097 Development Of New International Classification Criteria For Antiphospholipid Syndrome: Phase Iii Case Collection Results. BMJ Publishing Group Ltd; 2020
• 13 Chayoua W, Kelchtermans H, Gris JC. et al. The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost 2020; 18: 169-79
• 14 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18: 2828-39
• 15 Cervera R, Conti F, Doria A. et al. Does seronegative antiphospholipid syndrome really exist?. Autoimmun Rev 2012; 11: 581-584
• 16 Conti F, Andreoli L, Crisafulli F. et al. Does seronegative obstetric APS exist? “pro” and “cons”. Autoimmun Rev 2019; 18: 102407
• 17 Tang Z, Shi H, Liu H-L. et al Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’. Annals of the Rheumatic Diseases. 2023 ard-2023-225013
• 18 Pires Da Rosa G, Rodríguez-Pintó I, Cervera R. et al. Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines. Expert Rev Hematol 2021; 14: 457-66
• 19 Miro-Mur FA, Alijotas-Reig J, Anunciacion-Llunell A. et al Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’ by Barbhaiya <em>et al.</em>. Annals of the Rheumatic Diseases. 2023 ard-2023-225042
• 20 Erkan D, Sciascia S, Bertolaccini ML. et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. Current Rheumatology Reports 2021; 23: 45